Alice Shaw, Novartis' director of translational oncology
Novartis jumps into the KRAS race with a positive early snapshot — and a full slate of trials planned for ambitious bid to unseat Amgen
NEW ORLEANS — Amgen may have won the race to first approval among the KRAS G12C rivals, but that hasn’t deterred Novartis from unveiling an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
